Whilst the NHS makes the UK a potentially attractive place for international investment in regenerative medicine, problems in our regulatory arrangements and a lack of co-ordinated leadership on the issue is holding back the chance to deliver improvements. Research indicates that there is likely to be a GBP44bn to GBP54bn NHS funding gap by 2022 and that management of chronic disease accounts for around 75% of all UK health costs. Regenerative medicine has the potential to provide innovative treatments for a wide range of chronic diseases such as diabetes and heart disease, and such treatments could be a major benefit to the UK public purse as well as providing health benefits. The Committee makes a number of recommendations including: the Health Research Authority should take steps to streamline the overall regulatory system for regenerative medicine; the National Institute for Health Research should set up a regenerative medicine stream of its clinical research network to assist with design of clinical trials; the Department for Business, Innovation and Skills should invest in manufacturing facilities to support the scale-up of treatments in mid to late stage clinical development; the Department of Health should develop a strategy to ensure the NHS is ready to provide regenerative treatments; Government must explore innovative funding models to further support the field; and the National Institute for Health and Care Excellence (NICE) must review its evaluation process to ensure that regenerative treatments, which can have a high start-up cost but could represent big savings for the NHS in the long run, do not lose out on funding